Clinical trials: open to volunteers, sponsored by M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia (CLL)
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
- Trial name
- NCT07508995
- Testing
- BGB-16673, BGB-11417
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
This is a Phase Ia/Ib, open-label study evaluating the concurrent administration of zanidatamab and zongertinib in patients with advanced, unresectable, or metastatic non-small lung cancer harboring HER2 alterations.
- Trial name
- NCT07899801
- Testing
- Zanidatamab, Zongertinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Informed Consent
Chatbot Implementation In The Clinical Informed Consent Process
The purpose of this study is to determine the feasibility of implementing the chatbot "CoCo" in the IC process for research studies.
- Trial name
- NCT07756515
- Testing
- CoCo Chatbot
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphodepleting Chemotherapy, Myeloid Malignancies
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
- Trial name
- NCT06383572
- Testing
- Cyclophosphamide, Fludarabine phosphate, Decitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma, Tumor
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
- Trial name
- NCT06108232
- Testing
- Obinutuzumab, CC-99282
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Amputation
Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation
This clinical trial evaluates two surgical techniques (targeted muscle re-innervation [TMR] and regenerative peripheral nerve interfaces [RPNI]) alone and in combination for the alleviation of chronic residual limb and phantom…
- Trial name
- NCT06840262
- Testing
- Questionnaire Administration, Regenerative Peripheral Nerve Interface Surgery, Targeted Muscle Reinnervation
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
- Trial name
- NCT05776979
- Testing
- Isatuximab, lenalidomide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Communication Skills, Professionalism
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)
To learn about how patients view a doctor's compassion, communication skills, and professionalism based on whether the doctor uses the Electronic Health Record (EHR) during a visit with a patient.
- Conditions
- Communication Skills, Professionalism, Randomized Controlled Trial, Perception
- Trial name
- NCT07089953
- Testing
- Questionnaire, Video
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancers, Fatigue
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational…
- Trial name
- NCT06085716
- Testing
- Psychoeducational Intervention
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- M.D. Anderson Cancer Center
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Ropeginterferon, Alfa-2b
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations.
- Conditions
- Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
- Trial name
- NCT07646821
- Testing
- ropeginterferon alfa- 2b, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Tumors
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
The goal of this research study is to find out if using an updated version of standard computer software (called RayStation) for confirming that thermal ablation treatment was able to destroy all tumor cells including a safety…
- Trial name
- NCT07877220
- Testing
- RayAblation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
- Trial name
- NCT05287451
- Testing
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Thyroid Cancer
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination.
- Trial name
- NCT07470489
- Testing
- Cemiplimab, Zanzalintinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
- Trial name
- NCT07318389
- Testing
- SOC (Standard of care), Bevacizumab, Cetuximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Evaluating, Intermittent Fasting
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic…
- Conditions
- Evaluating, Intermittent Fasting, Pancreatic Cancer
- Trial name
- NCT07513116
- Testing
- intermittent fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Long Term, Quality of Life
Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) at MD Anderson…
- Conditions
- Long Term, Quality of Life, Recurrence Free, Cytoreductive Surgery
- Trial name
- NCT07871760
- Testing
- Questionnaire and Physical Exam
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid…
- Trial name
- NCT02390635
- Testing
- Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Leiomyosarcoma
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
- Trial name
- NCT07076186
- Testing
- Trabectedin, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center